Eagle Pharmaceuticals, Inc.

OTCPK:EGRX Stock Report

Market Cap: US$8.7m

Eagle Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 0/6

Insufficient data to determine the health of Eagle Pharmaceuticals

Key information

n/a

Debt to equity ratio

n/a

Debt

Interest coverage ration/a
Cashn/a
Equityn/a
Total liabilitiesn/a
Total assetsn/a

Recent financial health updates

Recent updates

Analysis Article • Sep 21

Is Eagle Pharmaceuticals (NASDAQ:EGRX) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Jul 13

Calculating The Fair Value Of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Key Insights The projected fair value for Eagle Pharmaceuticals is US$20.05 based on 2 Stage Free Cash Flow to Equity...
Analysis Article • Jun 21

Eagle Pharmaceuticals (NASDAQ:EGRX) Seems To Use Debt Quite Sensibly

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Oct 27

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Seeking Alpha • Oct 12

Eagle files for FDA nod to start trial of CAL02 for bacterial pneumonia

Eagle Pharmaceuticals (NASDAQ:EGRX) filed an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) seeking clearance to start a trial of CAL02 for treating severe community-acquired bacterial pneumonia (SCABP). The IND filing includes a protocol for a global phase 2 trial of CAL02, when added to standard of care therapy, in patients with SCABP. The study plans to enroll ~276 patients with SCABP at 120 sites worldwide and enrollment is expected from start of  2023.
Seeking Alpha • Sep 27

Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose

Eagle Pharmaceuticals (NASDAQ:EGRX) said Enalare Therapeutics secured a contract for up to $50.3M from the Biomedical Advanced Research and Development Authority (BARDA) to develop an an intramuscular formulation of ENA-001 for patients experiencing community drug overdose. ENA-001 is a new chemical entity with a unique mechanism of action which is being developed as a respiratory stimulant for patients experiencing acute respiratory depression, Eagle said in a Sept. 27 press release. "The pre-clinical work is going very well, and the BARDA contract provides support along the development and regulatory pathway toward FDA approval of ENA-001 for use in the United States," said Eagle President and CEO Scott Tarriff. Eagle added that the new award builds on an existing partnership between Enalare and the BARDA DRIVe ReDIRECT (Repurposing Drugs in Response to Chemical Threats) program. BARDA operates under the U.S. Department of Health and Human Services. Eagle noted that in August 2022, it made an equity investment of $12.5M in Enalare, and committed to invest another $12.5M six months later and two potential follow-on equity investments of $15M each, contingent upon reaching certain objectives.
Seeking Alpha • Aug 18

Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court

Eagle Pharmaceuticals (NASDAQ:EGRX) announced Thursday that a federal appeals court ruled the company's blood pressure therapy vasopressin did not infringe on any of the patents claimed by Par Pharmaceutical, Inc., a unit of the generic drug maker Endo International (ENDP). The decision affirms a District Court ruling after Par alleged in a 2018 lawsuit that Eagle (EGRX) infringed several of its patents. Subsequently, the U.S. District Court for the District of Delaware held that Eagle (EGRX) did not infringe any of the patents, and Par appealed. Eagle (EGRX) won FDA approval for its generic vasopressin in December. The injection, indicated to raise blood pressure in adults with vasodilatory shock, added $11.3M in sales for Eagle (EGRX) during the second quarter of 2022.
Analysis Article • Aug 15

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Analysts Are More Bearish Than They Used To Be

Today is shaping up negative for Eagle Pharmaceuticals, Inc. ( NASDAQ:EGRX ) shareholders, with the analysts delivering...
Seeking Alpha • Aug 09

Eagle Pharmaceuticals Non-GAAP EPS of $1.56 misses by $1.80, revenue of $74.1M misses by $42.79M

Eagle Pharmaceuticals press release (NASDAQ:EGRX): Q2 Non-GAAP EPS of $1.56 misses by $1.80. Revenue of $74.1M (+54.0% Y/Y) misses by $42.79M.
Analysis Article • Jul 06

These 4 Measures Indicate That Eagle Pharmaceuticals (NASDAQ:EGRX) Is Using Debt Safely

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article • Apr 29

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Intrinsic Value Is Potentially 42% Above Its Share Price

Does the April share price for Eagle Pharmaceuticals, Inc. ( NASDAQ:EGRX ) reflect what it's really worth? Today, we...

Financial Position Analysis

Short Term Liabilities: Insufficient data to determine if EGRX's short term assets cover its short term liabilities.

Long Term Liabilities: Insufficient data to determine if EGRX's short term assets cover its long term liabilities.

Debt to Equity History and Analysis

Debt Level: Insufficient data to calculate EGRX's net debt to equity ratio to determine if it is satisfactory.

Reducing Debt: Insufficient data to determine if EGRX's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: Insufficient data to determine if EGRX's debt is well covered by operating cash flow.

Interest Coverage: Insufficient data to determine if EGRX's interest payments on its debt are well covered by EBIT.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/05 05:42
End of Day Share Price 2026/06/26 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eagle Pharmaceuticals, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Louise ChenCantor Fitzgerald & Co.
Irina Rivkind KofflerMizuho Securities USA LLC
David AmsellemPiper Sandler Companies